155 related articles for article (PubMed ID: 32187881)
1. Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Bays HE; Kozlovski P; Shao Q; Proot P; Keefe D
Obesity (Silver Spring); 2020 May; 28(5):870-881. PubMed ID: 32187881
[TBL] [Abstract][Full Text] [Related]
2. The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
He YL; Haynes W; Meyers CD; Amer A; Zhang Y; Mahling P; Mendonza AE; Ma S; Chutkow W; Bachman E
Diabetes Obes Metab; 2019 Jun; 21(6):1311-1321. PubMed ID: 30724002
[TBL] [Abstract][Full Text] [Related]
3. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity.
Yokote K; Sano M; Tsumiyama I; Keefe D
Diabetes Obes Metab; 2020 Jul; 22(7):1102-1110. PubMed ID: 32072763
[TBL] [Abstract][Full Text] [Related]
4. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study.
Harrison SA; Manghi FP; Smith WB; Alpenidze D; Aizenberg D; Klarenbeek N; Chen CY; Zuckerman E; Ravussin E; Charatcharoenwitthaya P; Cheng PN; Katchman H; Klein S; Ben-Ari Z; Mendonza AE; Zhang Y; Martic M; Ma S; Kao S; Tanner S; Pachori A; Badman MK; He Y; Ukomadu C; Sicard E
Nat Med; 2022 Jul; 28(7):1432-1438. PubMed ID: 35725922
[TBL] [Abstract][Full Text] [Related]
5. Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial.
Tan S; Ignatenko S; Wagner F; Dokras A; Seufert J; Zwanziger D; Dunschen K; Zakaria M; Huseinovic N; Basson CT; Mahling P; Fuhrer D; Hinder M
Diabetes Obes Metab; 2021 Nov; 23(11):2595-2599. PubMed ID: 34263971
[TBL] [Abstract][Full Text] [Related]
6. Investigation and Management of Stool Frequency and Consistency Associated With SGLT1 Inhibition by Reducing Dietary Carbohydrate: A Randomized Trial.
He Y; Schofield J; Mahling P; Mendonza AE; Hinder M
Clin Pharmacol Ther; 2020 Nov; 108(5):995-1002. PubMed ID: 32236953
[TBL] [Abstract][Full Text] [Related]
7. Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.
de Boer RA; Núñez J; Kozlovski P; Wang Y; Proot P; Keefe D
Br J Clin Pharmacol; 2020 Jul; 86(7):1346-1356. PubMed ID: 32068914
[TBL] [Abstract][Full Text] [Related]
8. Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
He Y; Pachori A; Chen P; Ma S; Mendonza AE; Amer A; Marbury TC; Hinder M
Diabetes Obes Metab; 2021 May; 23(5):1182-1190. PubMed ID: 33512754
[TBL] [Abstract][Full Text] [Related]
9. Double-Blind, Randomized, Three-Armed, Placebo-Controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects.
Uebelhack R; Bongartz U; Seibt S; Bothe G; Chong PW; De Costa P; Wszelaki N
J Obes; 2019; 2019():3412952. PubMed ID: 30863632
[TBL] [Abstract][Full Text] [Related]
10. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
11. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
12. Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis.
Zheng H; Liu M; Li S; Shi Q; Zhang S; Zhou Y; Su N
Front Endocrinol (Lausanne); 2021; 12():706914. PubMed ID: 34484120
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects.
Kudiganti V; Kodur RR; Kodur SR; Halemane M; Deep DK
Lipids Health Dis; 2016 Aug; 15(1):136. PubMed ID: 27558585
[TBL] [Abstract][Full Text] [Related]
14. Dose-dependent efficacy and safety of licogliflozin on obese adults: A systematic review and meta-analysis of randomized controlled trials.
Zaki AM; Abo-Elnour DE; Abdalla YE; Hassan RY; Salama MK; Elboraay T; Abdelhaleem IA
Diabetes Metab Syndr; 2022 Nov; 16(11):102657. PubMed ID: 36335885
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a novel herbal formulation for weight loss demonstrated in a 16-week randomized, double-blind, placebo-controlled clinical trial with healthy overweight adults.
Dixit K; Kamath DV; Alluri KV; Davis BA
Diabetes Obes Metab; 2018 Nov; 20(11):2633-2641. PubMed ID: 29923305
[TBL] [Abstract][Full Text] [Related]
16. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
17. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and excretion of licogliflozin, a dual inhibitor of SGLT1/2, in rats, dogs, and humans.
Wang-Lakshman L; Mendonza AE; Huber R; Walles M; He Y; Jarugula V
Xenobiotica; 2021 Apr; 51(4):413-426. PubMed ID: 33413022
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
Davies MJ; Bergenstal R; Bode B; Kushner RF; Lewin A; Skjøth TV; Andreasen AH; Jensen CB; DeFronzo RA;
JAMA; 2015 Aug; 314(7):687-99. PubMed ID: 26284720
[TBL] [Abstract][Full Text] [Related]
20. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
